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Abstract
Background: The selective estrogen receptor modulators
(SERMs) raloxifene and tamoxifen are triphenylethylene deriva-
tives that affect transcriptional regulation by the estrogen
receptors (ERK and ERL) but show different effects in different
tissues. A third triphenylethylene derivative, GW-5638, displays
tissue selectivity in rats identical to that of raloxifene, suggesting
that GW-5638 and raloxifene share a mechanism of action that is
different from that of tamoxifen.
Results : Both GW-5638 and its hydroxylated analog GW-7604
were tested for their ability to bind to ERK and ERL and their
ability to affect transcription of ERK and ERL at a consensus
estrogen response element and an ER/AP-1 response element. The
drugs were found to have the same affinity for ERK and ERL,
although they were also found to activate transcription from an
AP-1 promoter element more potently with ERL than with ERK.
Derivatives of GW-5638 with alterations at the carboxylic acid still
showed increased ERL potency compared to ERK, but the
magnitude of the activation with ERK was much higher than
with ERL.
Conclusions: Despite similar binding affinities to isolated ERK
and ERL, GW-5638 and GW-7604 show markedly lower EC50
values with ERL at an AP-1-driven promoter as compared to
ERK. This suggests that the two compounds produce a more
active ER/AP-1 conformation of the ER/AP-1 transcription factor
complex when bound to ERL than when bound to ERK. ß 2001
Elsevier Science Ltd. All rights reserved.
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1. Introduction
The estrogen receptors (ERK and ERL) are members of
a large family of nuclear receptors that activate or repress
transcription of genes in response to small molecule li-
gands [1]. Estrogen receptors play an important regulatory
role in the reproductive, skeletal and cardiovascular sys-
tems and are validated therapeutic targets for diseases
such as breast cancer and osteoporosis. A number of
drugs have been developed that target the ER and many
of these show di¡erent activities in di¡erent tissues [2]. For
example, the breast cancer drug tamoxifen (2) functions as
an antiestrogen in breast tissue, but mimics the activity of
the physiological hormone, estradiol (1), in the uterus and
bone. In contrast, the osteoporosis drug raloxifene (3) acts
as an antiestrogen in both breast and uterine tissue while
being estrogenic in bone. (Structures of the compounds
used in this study are shown in Fig. 1.)
One explanation for the di¡erent tissue e¡ects of these
drugs is that a ligand may elicit di¡erent responses when
the receptor binds to di¡erent e¡ector sites [3,4]. The es-
trogen receptor regulates transcription through binding to
estrogen response elements (EREs) in the upstream pro-
moter regions of target genes. At present, the most studied
consensus ERE is the palindromic core sequence
GGTCANNNTGACC which is recognized by homodi-
meric liganded ERs [5,6]. However, there is a growing
body of evidence suggesting that there are important
DNA e¡ector sites for the estrogen receptors that di¡er
signi¢cantly in sequence from the consensus ERE. These
non-classical sites do not necessarily require protein^DNA
interactions between the receptor and the promoter ele-
ment, but instead can regulate transcription through
protein^protein interactions between the receptor and
other transcription factors, such as Sp-1 and AP-1 [7,8].
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Through receptor interactions with di¡erent response ele-
ments, the same ligand can cause activation or repression
of di¡erent sets of genes. One of the most interesting fea-
tures about these non-classical response elements is that
antiestrogens can induce transcriptional activation
through ERs at these sites.
A second variable to consider for tissue selectivity is
that there are two di¡erent subtypes of the estrogen re-
ceptor, ERK and ERL. The two subtypes share a high
degree of sequence similarity in the regions of the receptor
responsible for DNA binding and ligand binding, but dif-
fer substantially in the A/B and F regions of the receptor.
It has been shown that the response to both estrogens and
antiestrogens at an AP-1 site depends on the subtype of
the receptor [9] ; estradiol elicits transcriptional activation
with ERK, but transcriptional repression with ERL. The
two ER subtypes also respond di¡erently to raloxifene at
an AP-1 site; ERL shows much stronger activation than
ERK in response to raloxifene. Subtype-selective activities
have also been seen at other classical and non-classical
estrogen response elements [7,10,11].
A triphenylethylene derivative, GW-5638 (4), has been
reported to have tissue-selective e¡ects similar to raloxi-
fene, in that it is estrogenic in bone and antiestrogenic in
breast and uterine tissue [12,13]. There are two interesting
features about GW-5638: (1) it shows a tissue pro¢le sim-
ilar to raloxifene despite having the ethyltriphenylethylene
sca¡old of tamoxifen, and (2) GW-5638 contains a car-
boxylic acid on the side chain extending from the central
ethyltriphenylethylene core which di¡ers from the amine-
containing side chains of both tamoxifen and raloxifene.
To date, there have been no reports of induction of tran-
scription by GW-5638; only antiestrogenic in vitro activ-
ities have been reported with this compound. Here, we
show that GW-5638 can induce ER-dependent transcrip-
tional activation at an AP-1 site and that it does so in an
ERL-selective way. We also show that the negative charge
of the carboxylic acid side chain is an essential feature of
this ERL-selective response.
2. Results
2.1. Synthesis of GW-5638 and derivatives
Both GW-5638 and its more potent, hydroxylated ana-
log, GW-7604, were synthesized following a published syn-
thetic route for GW-5638 [12]. In the case of GW-7604,
which contains a hydroxyl group on one of the phenyl
rings, the synthesis was modi¢ed to carry through the
hydroxyl group protected as a t-butyl ether (Scheme 1).
While the synthesis of GW-5638 produces only the desired
Z double bond geometry at the triphenylethylene core, the
synthesis of GW-7604 produces a mixture of Z and E
isomers. The ole¢n isomerization occurs in the bromina-
tion step that provides bromide 11. We investigated a
variety of alternative conditions to prevent this isomeriza-
tion but all attempts were unsuccessful. However, we were
able to ¢nd conditions to precipitate the undesired Z iso-
mer of GW-7604 such that preparations of pure Z and
E/Z mixtures could be obtained. A Horner^Emmons re-
action was used on an intermediate in the synthesis of
Fig. 1. Compounds used in this study.
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GW-5638 and GW-7604 (Scheme 2) to make analogs
where the carboxylic acid was replaced with a methyl ke-
tone (8 and 9). The synthesis of the methyl ketone deriv-
ative of GW-7604 produced a mixture of Z and E isomers
that were inseparable.
2.2. Ligand binding to ERK and ERL
All compounds were tested for binding a⁄nity to ERK
and ERL in a competition assay with radiolabeled estra-
diol (Table 1). GW-5638 and GW-7604 did not show bind-
ing selectivity between ERK and ERL ; GW-5638 bound to
both ERs with 5^8% of the a⁄nity of estradiol, whereas
GW-7604 bound to both ERs with 15% of the a⁄nity of
estradiol. The methyl ketone derivatives 8 and 9 had
roughly 5^10-fold lower binding a⁄nity for ERK and
ERL compared to their carboxyl analogs suggesting that
the acid moiety is involved in an important binding con-
tact. One of the well-documented di⁄culties of working
with the 4-hydroxylated tamoxifen derivatives is the facile
E/Z isomerization, particularly in the cell-based assays
used to measure activity [14,15]. Compared to the E/Z
mixture, the pure Z isomer of GW-7604 shows 8-fold low-
er a⁄nity for ERK and 15-fold lower a⁄nity for ERL. A
similar di¡erence was seen between the two isomers of
hydroxytamoxifen in binding to ERK [15]. In that case,
isolation of hydroxytamoxifen from estrogen receptors in
cell-based assays resulted in recovery of only the higher
a⁄nity form [15]. With a similar di¡erence in binding
a⁄nity for the two isomers of GW-7604, any activity
seen in cell-based assays with the E/Z mixture can be
attributed to the E isomer since it will be the predominant
isomer that is bound to the receptor.
2.3. Ligand activation at ERE and AP-1 sites
GW-5638 and GW-7604 were then tested for their ef-
fects on ER-mediated transcription in HeLa cells using
Scheme 1.
Table 1
Relative binding a⁄nities (RBA) of ligands to full length ERK or ERL calculated as described in Section 5
Ligand RBA
ERK ERL
Estradiol (1) 100 100
4-Hydroxytamoxifen (3) 36 43
Raloxifene (4) 34 76
GW-5638 (5) 5 8
GW-7604 (6) (Z and E isomers) 15 15
GW-7604 (Z isomer) 2 1
Ketone (8) 1.3 0.2
4-Hydroxyketone (9) (Z and E isomers) 2.4 1
Relative binding a⁄nities are expressed as a percentage of the potency of estradiol. Under the experimental conditions described in Section 5, estradiol
was found to have an IC50 of 5 nM for ERK and 3 nM for ERL.
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reporter gene assays. The two reporter gene constructs
were regulated either by a consensus estrogen response
element (ERE) mentioned above, or by an AP-1 response
element from the upstream region of the collagenase gene.
In our studies, a G400V point mutant of ERK was used.
This mutant, called HE0, shows lower ligand-independent
activity and has been described previously with the AP-1
response element [9]. In our present studies, as before, the
ligand-dependent activity of HE0 was no di¡erent from
wild-type ERK for any of the compounds tested. With
an ERE-driven luciferase reporter, GW-5638 and GW-
7604 antagonized an estradiol response with ERK and
ERL (Fig. 2), in agreement with previous reports [13].
With an AP-1-driven luciferase reporter, di¡erences in li-
gand activation between ERK and ERL were seen with
GW-5638 and GW-7604. Dose^response curves for GW-
5638 and GW-7604 show that the two compounds activate
transcription with ERL more potently at the AP-1 site
than with ERK ; the EC50 value of induction with ERL
is at least 15 times more potent than with ERK for GW-
5638 and approximately 50 times more potent for GW-
7604 (Fig. 3). In contrast, 4-hydroxytamoxifen and ralox-
ifene induce responses with ERK and ERL that di¡er only
in the magnitude of the transactivation. Tamoxifen in-
duces a stronger response with ERK than with ERL and
raloxifene induces a stronger response with ERL than with
ERK, but both compounds have similar EC50 values for
reporter induction. To our knowledge, this is the ¢rst re-
port of ER-mediated induction of transcriptional activa-
tion by GW-5638 or GW-7604.
When the carboxamide (7) and the ketone analogs (8
and 9) were tested in transactivation assays at an ERE
site, all three compounds were found to be antagonists
of estradiol activation with both ERK and ERL. However
at the AP-1 site, agonism was observed and the carbox-
amide (7) and 4-hydroxyketone (9) showed much stronger
activation with ERK than with ERL (Fig. 4). In a dose^
response experiment, the hydroxyketone (9) was found to
activate ERL more potently that ERK, yet showed a much
higher magnitude of activation with ERK than with ERL.
The higher level of activation with ERK compared to ERL
resembles the pro¢le of 4-hydroxytamoxifen rather than
that of GW-5638 and GW-7604 (Fig. 3).
Scheme 2.
Fig. 2. Competition of (A) GW-5638 (5) and (B) GW-7604 (6) versus 0.1 nM estradiol in transient transfection assay of HeLa cells with ERK (orange)
and ERL (purple) and the vitellogenin A2 ERE-tk-driven luciferase reporter gene. Curve represents the best ¢t to a single-site competition binding mod-
el. 100% activation represents the activation with 0.1 nM estradiol alone.
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3. Discussion
3.1. Mechanism of ERL-selective signaling at the AP-1 site
Ligand binding experiments show that there is no ERK/
ERL binding selectivity for GW-5638, GW7604 or ketone
derivatives 8 and 9 (Table 1). These compounds have a
weaker binding a⁄nity than 4-hydroxytamoxifen and ra-
loxifene, but like 4-hydroxytamoxifen and raloxifene, the
a⁄nity is approximately the same with ERK and ERL.
Furthermore, competition experiments at the ERE site
show that these compounds have similar IC50 values
with ERK and ERL for antagonism of an estradiol re-
sponse, a property that is again similar to 4-hydroxyta-
moxifen and raloxifene (Table 2). However, the properties
of the compounds at the AP-1 site di¡er from those of 4-
hydroxytamoxifen and raloxifene. All of the compounds
are agonists of transactivation at AP-1 and show greater
potency with ERL than with ERK (Table 2). GW-7604 is
approximately 50 times more potent at inducing activation
with ERL than with ERK. This di¡ers from 4-hydroxyta-
moxifen and raloxifene, which show similar potencies with
Fig. 3. Dose^response curves for transient transfections with the AP-1-driven luciferase reporter gene using (A) 4-hydroxytamoxifen, (B) raloxifene, (C)
GW-5638 (5), and (D) GW-7604 (6). Data for transfections with ERK shown in orange and data for ERL shown in purple. Fold activation determined
relative to the response with no hormone present. Curve represents best ¢t of data using a single-site sigmoidal dose^response model.
Table 2
Comparison of ligand activities in competition experiments at an ERE-driven reporter gene and in activation experiments at an AP-1-driven reporter
gene
IC50 at ERE EC50 at AP-1 site
ERK ERL ERK ERL
GW-5638 2.6 WM 3.8 WM s 10 WM 730 nM
GW-7604 130 nM 43 nM 240 nM 5.1 nM
Ketone (8) 5.6 WM 1.2 WM s 10 WM s 10 WM
4-Hydroxyketone (9) 50 nM 15 nM 2.2 WM 110 nM
Competition experiments performed versus 0.1 nM estradiol. IC50 values determined using a single binding site competition model. EC50 values deter-
mined using a single binding site sigmoidal dose^response model.
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ERK and ERL but di¡erent levels of maximum induction
(Fig. 3). The 4-hydroxyketone derivative (9) shows di¡er-
ences between ERK and ERL in both the potency and the
level of maximum induction. Taken together, these results
indicate an unusual situation in which ligand binding af-
¢nity for the two estrogen receptors of GW-5638 and GW-
7604 is not directly connected to potency of ligand induc-
tion at an AP-1 site.
This suggests that there may be di¡erent mechanisms of
ligand induction for ERK and ERL at AP-1 sites. Ligand
binding by the estrogen receptor is merely the ¢rst step in
a pathway that leads to transcriptional activation. Other
accessory proteins are known to interact with the receptor
after ligand is bound to form a transcriptionally active
complex [16]. The fact that GW-5638 and GW-7604 as
well as their ketone derivatives (8 and 9) are able to acti-
vate transcription at the AP-1 site more potently with ERL
compared to ERK suggests that the accessory proteins
necessary for activation are recruited more e⁄ciently by
liganded ERL than by liganded ERK. GW-5638 and GW-
7604 bind to ERL to produce a strongly active ER/AP-1
whereas the same two drugs bind to ERK to produce a
weakly active ER/AP-1 conformation. It is important to
note that in this situation, the a⁄nity of the ligand for
each receptor subtype is less important in determining
the overall activity of the compound than the ability of
the ligand^receptor complex to transduce signals to the
basal transcription machinery.
The work reported here demonstrates that compounds
without binding selectivity for ERK and ERL can still
show signi¢cant ERK/ERL selectivity in ligand induction.
Mutational analysis suggests that domains in addition to
the ligand binding domain are important in binding puta-
tive accessory proteins involved in the AP-1 response [17].
This means that ligand binding can cause di¡erent inter-
domain interactions in ERK compared to ERL and that
this may be the underlying explanation for the di¡erences
in the AP-1 activity of the two subtypes in response to
di¡erent ligands. In support of this model, interchanging
the highly di¡erent N-terminal domains of ERK and ERL
has a dramatic e¡ect on the response of the two subtypes
to tamoxifen and raloxifene at the AP-1 site [18].
3.2. Correlating SERM activity with the AP-1 response
A signature feature of compounds that target the estro-
gen receptor is that they often show di¡erent e¡ects in
di¡erent tissues. For instance tamoxifen has antiestrogenic
properties in breast tissue but estrogenic properties in ute-
rine and bone tissue. In contrast, raloxifene is antiestro-
genic in uterine tissue while still maintaining estrogenic
activity in bone. At the AP-1 site, raloxifene shows greater
activation with ERL compared to ERK whereas tamoxifen
shows greater activation with ERK. The possibility that
the activation of transcription at ERK via the AP-1 site
might be correlated with the estrogenic properties in ute-
rine tissue is further strengthened by this work. GW-5638
shows greater ERL activation at the AP-1 site while the
carboxamide analog (7) shows greater activation with
ERK. This can be correlated to the original report on
the compounds; GW-5638 lacked uterotrophic activity in
rats whereas estrogenic activity in the uterus was seen with
the carboxamide derivative [12].
4. Signi¢cance
This work further demonstrates that the estrogen recep-
tor (ER) subtype selectivity of a given ligand at an AP-1
site cannot be determined solely by binding a⁄nity to
ERK and ERL. In addition, a correlation is established
between the tissue estrogenic pro¢le of a panel of selective
estrogen receptor modulators (SERMs) and their activa-
tion pro¢le in an ER-mediated transcriptional assay.
Fig. 4. Dose^response curves for transient transfections with the AP-1-driven luciferase reporter gene using 4-hydroxyketone (9) and carboxamide (7).
Data for transfections with ERK shown in orange and data for ERL shown in purple. Fold activation determined relative to the response with no hor-
mone present. Curve represents best ¢t of data using a single-site sigmoidal dose^response model.
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5. Materials and methods
5.1. General procedures
The construction of the expression vectors for both hERK
(HE0) and hERL as well as the AP-1 regulated luciferase con-
struct (vColl73-luc) have been described [8,9]. The ERE-driven
luciferase reporter gene consists of two repeats of the upstream
region of the vitellogenin ERE promoter from 3331 to 3289,
followed by region 3109 to +45 of the thymilidate kinase up-
stream region and the luciferase gene. Whereas a point mutant of
ERK (HE0) that has a lower hormone-independent response was
used in these studies, previous experiments have shown that there
are no di¡erences in the responses of the HE0 mutant and the
wild-type ERK at the AP-1 site [9]. The longer form of ERL with
149 residues in the N-terminal domain was used in transfection
experiments. No signi¢cant di¡erences in the activation at either
the ERE or AP-1 site were observed with the shorter version of
ERL with 96 residues (data not shown). Proton and carbon-13
nuclear magnetic resonance spectra (1H NMR, 13C NMR) were
obtained on a Varian INOVA-400 (400 MHz) instrument; 1H
NMR chemical shifts are reported as N values in parts per million
(ppm) down¢eld from internal tetramethylsilane, or down¢eld
from the residual H2O peak in CD3OD; 13C NMR chemical
shifts are reported as N values with reference to the solvent
peak. High-resolution mass spectrometry (HRMS) was per-
formed by the National Bioorganic and Biomedical Mass Spec-
trometry Resource at UCSF.
5.2. Tissue culture, transfection and luciferase assays
HeLa cells were grown in 0.1 Wm ¢ltered DME supplemented
with 4.5 g/l glucose, 0.876 g/l glutamine, 100 mg/l streptomycin
sulfate, 100 units/ml of penicillin G and 10% newborn calf serum.
Cells were grown to a density of not more than 5U104 cells per
cm2. For transient transfection assays, cells were suspended in
0.5 ml electroporation bu¡er in 0.4 cm gap electroporation cu-
vettes at approximately 1.5U106 cells per cuvette with 5 Wg of the
reporter plasmid and the optimal amount of the receptor expres-
sion vector for ligand activation, determined previously to be 5 Wg
plasmid per transfection for the AP-1 response or 1 Wg expression
plasmid per transfection for the ERE response. The electropora-
tion bu¡er consisted of 0.2 Wm ¢ltered PBS and 0.1% glucose.
Cells were transfected by electroporation at a potential of 0.25 kV
and a capacitance of 960 mF. Transfected cells were pooled and
immediately resuspended in growth media supplemented as de-
scribed above with the exception that the newborn calf serum had
been treated with charcoal as described previously [9]. Cells were
plated into 6- or 12-well dishes at 2 ml per well at a density of
approximately 1U105 cells per well. After 2 h of incubation at
37‡C, hormones were added in 2 Wl of ethanol.
After 24 h of incubation at 37‡C, the cells were lysed by ¢rst
removing the media from the wells, washing with PBS and then
adding 0.2 ml of lysis bu¡er consisting of 100 mM potassium
phosphate (pH 7.5), 0.2% Triton X-100 and 1 mM DTT. After
10 min at room temperature, 0.1 ml of the lysate was combined
with 0.3 ml of the luciferase assay bu¡er consisting of 25 mM
glycylglycine, 15 mM MgSO4, 4 mM EGTA, 15 mM potassium
phosphate (pH 7.8) with the addition to a ¢nal concentration of
1 mM DTT, 2 mM ATP and 0.2 mM luciferin. Luminescence was
measured for 10 s with a Monolight 3010 luminometer (Analyt-
ical Luminescence Laboratory, San Diego, CA, USA). Each hor-
mone dose was performed in triplicate and the relative error was
determined by calculating the standard error of the three values
from the mean. Experiments were conducted multiple times to
ensure reproducibility of the results.
5.3. ER binding assays
The relative binding a⁄nity of compounds for ERK and ERL
was determined using a spin column assay with commercially
available full length forms of both ERK and ERL (PanVera
Corp, Madison, WI, USA). Receptor was added to a ¢nal con-
centration of 15 nM to a solution containing 10 mM Tris, pH 7.5,
10% glycerol, 2 mM DTT and 1 mg/ml BSA and 3 nM
[2,4,6,7,16,17-3H]estradiol at 4‡C. 100 Wl of the solution was
added to 1 Wl of the ligand in ethanol, mixed gently by pipetting
and incubated at 4‡C overnight. The mixture was then applied to
a micro spin column containing G-25 Sephadex (Harvard Appa-
ratus Inc.) equilibrated in binding bu¡er (minus tritiated estra-
diol) according to the manufacturer’s instructions. Bound estra-
diol was separated from free ligand by spinning at 2000Ug for
4 min at room temperature. The ¢ltrate was then added to 2.5 ml
of scintillant and counted in a liquid scintillation counter. Each
point in the binding curve represents the average of two separate
experiments and the curve was ¢t using a single binding site
competition model with the Prism statistical analysis software
package. The standard deviation was determined to be less than
0.2 log units from the EC50 value. Percent relative binding a⁄nity
was then determined by dividing the IC50 determined for unla-
beled estradiol by the ligand IC50 and multiplying that by 100.
5.4. Synthesis of compounds
5.4.1. (3E)-3-[4-[(1Z)-1,2-Diphenyl-1-butenyl]phenyl]-3-buten-
2-one (8)
A solution of potassium bis(trimethylsilyl)amide (0.5 M in tol-
uene) (253 Wl, 0.13 mmol) was added to a stirring 0‡C solution of
diethyl (2-oxopropyl)phosphonate (24 Wl, 0.13 mmol) in tetrahy-
drofuran (0.8 ml). After stirring for 15 min at 0‡C, the solution
was cooled to 378‡C, and a solution of 1,2-diphenyl-1-(4-formyl-
phenyl)-but-1-ene (33 mg, 0.11 mmol) (14)) [12] in tetrahydrofur-
an (0.4 ml) was added dropwise. The reaction was stirred at
378‡C for 5 min, then allowed to warm to room temperature
and stirred 20 h overnight. The solution was poured into satu-
rated sodium chloride, extracted with ethyl acetate, dried over
anhydrous magnesium sulfate, and solvent removed under re-
duced pressure. The crude oil was puri¢ed by £ash column chro-
matography (0^5% ethyl acetate^hexanes) to give 8 as a yellow
oil (13.3 mg, 0.038 mmol) in 36% yield: Rf 0.26 (10% ethyl ace-
tate^hexanes); 1H NMR (CDCl3) N 0.94 (t, J = 7.6 Hz, 3 H), 2.31
(s, 3 H), 2.48 (q, J = 7.6 Hz, 2 H), 6.56 (d, J = 16 Hz, 1 H), 6.90
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(d, J = 8.0 Hz, 2 H), 7.11^7.38 (m, 13 H); 13C NMR (CDCl3)
13.47, 27.50, 29.00, 127.43, 127.47, 127.84, 127.99, 128.16, 128.28,
128.57, 129.49, 129.58, 130.16, 130.76, 131.34, 138.05, 141.78,
143.21, 143.36, 198.41 ppm; HRMS (EI) exact mass calculated
for C26H24O: 352.1827, found: 352.1826.
5.4.2. Z-2-Phenyl-1-(4-tert-butoxyphenyl)-1-trimethylsilyl-but-1-
ene (10)
A solution of lithium 4-tert-butoxybenzene was prepared by
adding n-butyl lithium (2.5 M in hexanes) (3.17 ml, 7.94 mmol)
to a 378‡C solution of 4-tert-butoxybromobenzene (1.81 g, 7.94
mmol) in tetrahydrofuran (20 ml). The reaction was stirred at
378‡C for 30 min. In a separate £ask, anhydrous zinc chloride
(1.04 g, 7.94 mmol) was dissolved in tetrahydrofuran (23 ml) and
a solution of 4-tert-butoxyphenylzinc chloride was prepared by
adding the lithium 4-tert-butoxybenzene solution at such a rate
that a slow re£ux was maintained. The solution was re£uxed an
additional 30 min, then cooled to room temperature. Tetrakis-
(triphenylphosphine)palladium(0) (0.13 mmol) was added to a
solution of (E)-1-bromo-2-phenyl-1-trimethylsilyl-1-butene (1.5 g,
5.29 mmol) in tetrahydrofuran (6 ml) and stirred at 25‡C for
5 min. The 4-tert-butoxyphenyl zinc chloride solution was then
added and the reaction was re£uxed 17 h overnight. The solution
was cooled to room temperature, quenched with 3 N hydrochlor-
ic acid, extracted with hexanes, washed with saturated sodium
bicarbonate and dried over anhydrous magnesium sulfate. Sol-
vent was removed under reduced pressure. The crude product
was puri¢ed by £ash column chromatography (silica, 0^4%
ether^hexanes) to a¡ord 10 as a white crystalline solid (1.61 g,
4.56 mmol) in 86% yield: Rf 0.58 (10% ethyl acetate^hexanes);
1H NMR (CDCl3) N 0.36 (s, 9 H), 0.72 (t, J = 7.6 Hz, 3 H), 1.36
(s, 9 H), 2.15 (q, J = 7.6 Hz, 2 H), 6.89 (d, J = 8.4 Hz, 2 H), 6.95
(d, J = 8.4 Hz, 2 H), 7.21 (d, J = 6.4 Hz, 2 H), 7.27^7.34 (m, 3 H);
13C NMR (CDCl3) 0.10, 12.80, 28.89, 30.05, 78.03, 123.80,
126.68, 127.66, 128.37, 128.98, 139.64, 140.50, 144.00, 152.67,




To a solution of Z-2-phenyl-1-(4-tert-butoxyphenyl)-1-trime-
thylsilyl-but-1-ene (10) [19,20] (76.5 mg, 0.22 mmol) in dichloro-
methane (1 ml) at 378‡C, was added dropwise a 1 M solution of
bromine in dichloromethane, until the reaction was complete as
monitored by thin layer chromatography. The yellow solution
was poured into 10% sodium sul¢te, extracted with dichlorome-
thane, washed with saturated sodium chloride, dried over anhy-
drous magnesium sulfate and solvent removed under reduced
pressure to give an orange oil. The crude product was puri¢ed
by £ash column chromatography (0^5% ethyl acetate^hexanes) to
give 11 as a yellow oil (53.9 mg, 0.15 mmol) in 69% yield, deter-
mined by 1H NMR to be a 3:2 mixture of Z :E isomers: Rf 0.61
(20% ethyl acetate^hexanes); 1H NMR (CDCl3) N 0.79 (t, J = 7.6
Hz, 3 H, Z isomer), 0.96 (t, J = 7.6 Hz, 2 H, E isomer), 1.19 (s,
6 H, E isomer), 1.31 (s, 9 H, Z isomer), 2.27 (q, J = 7.6 Hz, 2 H,
Z isomer), 2.72 (q, J = 7.6 Hz, 1.3 H E isomer), 6.61 (d, J = 8.8
Hz, 1 H), 6.90^7.00 (m, 6 H), 7.17^7.26 (m, 6 H), 7.30^7.32 (m,
2 H); 13C NMR (CDCl3) 11.68, 13.06, 28.77, 28.90, 29.50, 33.03,
78.63, 78.81, 118.74, 120.50, 122.99, 123.42, 126.57, 127.10,
127.83, 128.13, 128.30, 129.11, 129.61, 130.80, 135.48, 135.95,
140.54, 142.57, 144.03, 144.54, 154.52, 155.39 ppm; HRMS (EI)
exact mass calculated for C20H23OBr: 360.0912, found: 360.0977.
5.4.4. E-2-Phenyl-1-(4-tert-butoxyphenyl)-1-(4-formylphenyl)-
but-1-ene (12)
To a £ask containing a 1-bromo-2-phenyl-1-(4-tert-butoxy-
phenyl)-but-1-ene (11) isomer mixture (91.2 mg, 0.25 mmol)
was added 4-formylphenylboronic acid (41.9 mg, 0.28 mmol),
potassium £uoride (48.7 mg, 0.84 mmol) and tris(dibenzylidene-
acetone)dipalladium(0)^chloroform adduct (1.31 mg, 0.0013
mmol). After dissolving in tetrahydrofuran (1 ml), a 0.12 M so-
lution of tri-tert-butylphosphine (0.62 mg, 0.003 mmol) in tetra-
hydrofuran was added [21]. The reaction turned from red to
brown in 15 min, and was then stirred at 25‡C for 16 h overnight,
by which time it had turned a clear yellow with a black residue.
The solution was poured into saturated sodium bicarbonate, ex-
tracted with ethyl acetate, dried over anhydrous magnesium sul-
fate, and solvent removed under reduced pressure. The crude oil
was puri¢ed by £ash column chromatography (0^6% ether^hex-
anes) to give 12 as a yellow oil (43.8 mg, 0.11 mmol) in 46% yield,
determined by 1H NMR to be a 2:1 mixture of E :Z isomers: Rf
0.52 (20% ethyl acetate^hexanes); 1H NMR (CDCl3) N 0.95 (t,
J = 7.6 Hz, 4.5 H), 1.24 (s, 4.5 H, Z isomer), 1.38 (s, 9 H, E
isomer), 2.46 (q, J = 7.6 Hz, 1 H, Z isomer), 2.52 (q, J = 7.6
Hz, 2 H, E isomer), 6.64 (d, J = 8.4 Hz, 1 H), 6.72 (d, J = 8.4
Hz, 1 H), 6.98 (d, J = 8.4 Hz, 2 H), 7.03^7.16 (m, 11.5 H), 7.44 (d,
J = 8.0 Hz, 1 H), 7.52 (d, J = 8.0 Hz, 2 H), 7.88 (d, J = 8.0 Hz,
1 H), 9.83 (s, 1 H, E isomer), 10.03 (s, 1 H, Z isomer); 13C NMR
(CDCl3) 13.44, 13.50, 28.75 28.81, 28.90, 29.14, 78.31, 78.52,
123.16, 123.69, 126.38, 126.61, 127.81, 128.02, 128.87, 129.53,
129.55, 129.68, 130.02, 130.19, 131.18, 131.39, 133.71, 134.76,
137.12, 137.27, 137.46, 137.56, 141.58, 141.62, 143.21, 144.38,
150.04, 150.18, 153.60, 154.50, 191.91, 191.94 ppm; HRMS (EI)
exact mass calculated for C27H28O2 : 384.2089, found: 384.2090.
5.4.5. (3E)-3-[4-[(1E)-2-Phenyl-1-(4-tert-butoxyphenyl)-1-
butenyl]phenyl]-3-buten-2-one (15)
A solution of potassium bis(trimethylsilyl)amide (0.5 M in tol-
uene) (247 Wl, 0.12 mmol) was added to a stirring 0‡C solution of
diethyl (2-oxopropyl)phosphonate (47.5 Wl, 0.12 mmol) in tetra-
hydrofuran (0.8 ml). After stirring for 15 min at 0‡C, the solution
was cooled to 378‡C, and a solution of 2-phenyl-1-(4-tert-butoxy-
phenyl)-1-(4-formylphenyl)-but-1-ene (12) isomer mixture (39.6
mg, 0.10 mmol) in tetrahydrofuran (0.4 ml) was added dropwise.
The reaction was stirred at 378‡C for 5 min, then allowed to
warm to room temperature and stirred 20 h overnight. The solu-
tion was poured into saturated sodium chloride, extracted with
ethyl acetate, dried over anhydrous magnesium sulfate, and sol-
vent removed under reduced pressure. The crude oil was puri¢ed
by £ash column chromatography (0^10% ethyl acetate^hexanes)
to give 15 as a yellow oil (40.3 mg, 0.095 mmol) in 92% yield,
determined by 1H NMR to be a 3:2 mixture of E :Z isomers (at
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the triphenylethylene center): Rf 0.46 (30% ethyl acetate^hex-
anes); 1H NMR (CDCl3) N 0.94 (t, J = 7.6 Hz, 3 H, E isomer),
0.95 (t, J = 7.6 Hz, 2 H, Z isomer), 1.24 (s, 6 H, Z isomer), 1.38
(s, 9 H, E isomer), 2.31 (s, 3 H, E isomer), 2.39 (s, 2 H, Z isomer),
2.49 (q, J = 7.6 Hz, 1.7 H, Z isomer), 2.50 (q, J = 7.2 Hz, 2 H,
E isomer), 6.56 (d, J = 16.4 Hz, 1 H, E isomer), 6.62^7.31 (m,
21.7 H), 7.35 (d, J = 16.4 Hz, 1 H, E isomer), 7.51^7.55 (m,
1.3 H); 13C NMR (CDCl3) 13.47, 13.60, 27.35, 27.51, 28.75,
28.80, 28.90, 29.13, 78.24, 78.44, 123.10, 123.63, 126.20, 126.38,
126.75, 127.39, 127.75, 127.95, 128.14, 129.59, 130.01, 130.16,
131.20, 131.40, 131.62, 132.68, 137.55, 137.73, 137.71, 141.88,
141.98, 142.67, 143.23, 143.38, 145.96, 146.16, 153.44, 154.34,
198.35, 198.38 ppm; HRMS (EI) exact mass calculated for
C30H32O2 : 424.2402, found: 424.2406.
5.4.6. (3E)-3-[4-[(1E)-2-Phenyl-1-(4-hydroxyphenyl)-1-
butenyl]phenyl]-3-buten-2-one (9)
To a solution of a (3E)-3-[4-[2-phenyl-1-(4-tert-butoxyphenyl)-
1-butenyl]phenyl]-3-buten-2-one (15) isomer mixture (39.0 mg,
0.92 mmol) in dichloromethane (2 ml) was added tri£uoroacetic
acid (100 Wl) and 2,2,2-tri£uoroethanol (0.5 ml). The reaction was
stirred 12 h overnight at 25‡C, after which the solution was
poured into water, extracted with diethyl ether, washed with sa-
turated sodium bicarbonate, and the solvent removed under re-
duced pressure. The crude yellow solid was puri¢ed by prepara-
tive thin layer chromatography (30% ethyl acetate^hexanes, eluted
o¡ silica with ethyl acetate), to a¡ord 9 as a yellow solid (25.7
mg, 0.070 mmol) in 76% yield, determined by 1H NMR to be a
3:2 mixture of E :Z isomers (at the triphenylethylene center): Rf
0.40 (30% ethyl acetate^hexanes); 1H NMR (CDCl3) N 0.87 (t,
J = 7.6 Hz, 5 H), 2.25 (s, 3 H, E isomer), 2.32 (s, 2 H, Z isomer),
2.42 (q, J = 7.6 Hz, 1.7 H, Z isomer), 2.44 (q, J = 7.6 Hz, 2 H,
E isomer), 6.42 (d, J = 8.4 Hz, 1.3 H), 6.49 (d, J = 16.0 Hz, 1 H,
E isomer), 6.63^6.68 (m, 2H), 6.76 (d, J = 8.4 Hz, 2 H), 6.82 (d,
J = 8.4 Hz, 2 H), 7.01^7.22 (m, 13.7 H), 7.29 (d, J = 16.4 Hz, 1 H,
E isomer), 7.44^7.49 (m, 2 H); 13C NMR (CDCl3) 13.50, 13.55,
27.32, 27.48, 28.99, 29.14, 114.46, 115.16, 125.28, 126.24, 126.30,
126.39, 126.68, 127.43, 127.91, 127.96, 128.17, 128.21, 129.02,
129.60, 130.18, 130.83, 131.41, 131.55, 132.10, 132.62, 135.01,
135.34, 137.46, 137.59, 141.99, 142.00, 142.30, 143.36, 143.51,
143.69, 146.15, 146.46, 153.81, 154.69, 198.78 ppm; HRMS (EI)
exact mass calculated for C26H24O2 : 368.1776, found: 368.1774.
5.4.7. Methyl(2E)-3-[4-[(1E)-2-phenyl-1-(4-tert-butoxyphenyl)-
1-butenyl]phenyl]-2-propenoate (13)
A solution of potassium bis(trimethylsilyl)amide (0.5 M in tol-
uene) (288 Wl, 0.14 mmol) was added to a stirring 0‡C solution of
trimethyl phosphonoacetate (23 Wl, 0.12 mmol) in tetrahydrofur-
an (0.8 ml). After stirring for 15 min at 0‡C, the solution was
cooled to 378‡C, and a solution of a 2-phenyl-1-(4-tert-butoxy-
phenyl)-1-(4-formylphenyl)-but-1-ene (12) isomer mixture (46.2
mg, 0.10 mmol) in tetrahydrofuran (0.4 ml) was added dropwise.
The reaction was stirred at 378‡C for 5 min, then allowed to
warm to room temperature and stirred 16 h overnight. The solu-
tion was poured into water, extracted with diethyl ether, washed
with saturated sodium bicarbonate, dried over anhydrous magne-
sium sulfate, and the solvent removed under reduced pressure.
The crude oil was puri¢ed by preparative thin layer chromatog-
raphy (15% ethyl acetate^hexanes; eluted o¡ silica with ethyl
acetate) to give 13 as a yellow oil (50.8 mg, 0.12 mmol) in 96%
yield, determined by 1H NMR to be a 2:1 mixture of E :Z iso-
mers (at the triphenylethylene center): Rf 0.48 (20% ethyl ace-
tate^hexanes); 1H NMR (CDCl3) N 0.93 (t, J = 7.6 Hz, 4.5 H),
1.24 (s, 4.5 H, Z isomer), 1.37 (s, 9 H, E isomer), 2.49 (q, J = 7.6
Hz, 3 H), 3.75 (s, 3 H), 3.81 (s, 1.5 H), 6.28 (d, J = 16.0 Hz, 1 H,
E isomer), 6.45 (d, J = 16.0 Hz, 0.5 H, Z isomer), 6.63 (d, J = 8.8
Hz, 1 H), 6.73 (d, J = 8.4 Hz, 1 H), 6.88 (d, J = 8.4 Hz, 2 H), 6.97
(d, J = 8.4 Hz, 2 H), 7.06^7.17 (m, 11.5 H), 7.28 (d, J = 8.0 Hz,
1 H), 7.51 (d, J = 7.6 Hz, 1 H), 7.53 (d, J = 16.0 Hz, 1 H, E isomer),
7.71 (d, J = 16.0 Hz, 0.5 H); 13C NMR (CDCl3) 13.47, 13.55,
28.74, 28.79, 28.89, 29.12, 51.54, 51.65, 78.21, 78.41, 116.83,
117.31, 123.08, 123.61, 126.16, 126.35, 127.18, 127.29, 127.73,
127.93, 128.00, 129.47, 129.57, 129.99, 130.05, 131.19, 131.29,
131.59, 132.64, 137.58, 137.74, 137.76, 141.90, 141.98, 142.57,
143.21, 144.62, 144.69, 145.64, 145.87, 153.40, 154.30, 167.45,




To a 1:2 methanol:tetrahydrofuran (8 ml) solution of a meth-
yl(2E)-3-[4-[2-phenyl-1-(4-tert-butoxyphenyl)-1-butenyl]phenyl]-2-
propenoate (13) isomer mixture (50.8 mg, 0.12 mmol) at 25‡C,
was added dropwise a 0.2 M solution of aqueous potassium hy-
droxide (5.76 ml, 1.19 mmol). The reaction was stirred 24 h over-
night at 25‡C, then poured into 1 N hydrochloric acid. After
stirring for 10 min, the solution was extracted with methylene
chloride, dried over anhydrous magnesium sulfate, and the sol-
vent removed under reduced pressure. The crude oil was puri¢ed
by preparative thin layer chromatography (7.5% methanol^
chloroform; eluted o¡ silica using ethyl acetate) to give 16 as a
yellow oil (29.5 mg, 0.069 mmol) in 58% yield, determined by 1H
NMR to be a 2:1 mixture of E :Z isomers (at the triphenylethy-
lene center): Rf 0.31 (5% methanol^chloroform); 1H NMR
(CD3OD) N 0.85 (t, J = 7.6 Hz, 4.5 H), 1.14 (s, 4.5 H, Z isomer),
1.28 (s, 9 H, E isomer), 2.42 (q, J = 7.6 Hz, 3 H), 6.23 (d, J = 16.0
Hz, 1 H, E isomer), 6.31 (d, J = 16.0 Hz, 0.5 H, Z isomer), 6.55
(d, J = 8.4 Hz, 1 H), 6.69 (d, J = 8.8 Hz, 1 H), 6.82 (d, J = 8.4 Hz,
2 H), 6.92 (d, J = 8.8 Hz, 2 H), 7.01^7.10 (m, 9.5 H), 7.14 (d,
J = 8.4 Hz, 2 H), 7.21 (d, J = 8.0 Hz, 1 H), 7.42 (d, J = 15.6 Hz,
1 H, E isomer), 7.52 (d, J = 8.0 Hz, 1 H), 7.62 (d, J = 16.0 Hz,
0.5 H, Z isomer); 13C NMR (CD3OD) 13.77, 13.82, 29.10, 29.24,
29.76, 29.99, 79.50, 79.65, 118.64, 119.15, 119.62, 124.20, 124.87,
127.36, 127.55, 128.33, 128.88, 129.05, 129.16, 130.81, 131.13,
132.43, 133.23, 133.49, 134.32, 138.01, 139.30, 139.34, 139.45,
140.50, 142.92, 143.29, 143.33, 143.98, 144.55, 146.03, 146.34,
147.02, 147.09, 154.68, 155.62, 170.40 ppm; HRMS (EI) exact
mass calculated for C29H30O3 : 426.2195, found: 426.2195.
5.4.9. (2E)-3-[4-[(1E)-2-Phenyl-1-(4-hydroxyphenyl)-1-
butenyl]phenyl]-2-propenoic acid (GW-7604) (6)
To a solution of a (2E)-3-[4-[2-phenyl-1-(4-tert-butoxyphenyl)-
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1-butenyl]phenyl]-2-propenoic acid (16) isomer mixture (29.5 mg,
0.069 mmol) at 0‡C in dichloromethane (1 ml) was added 2,2,2-
tri£uoroethanol (0.5 ml), followed by tri£uoroacetic acid (1 ml).
The reaction was stirred for 10 min at 0‡C, then allowed to warm
to room temperature and stirred for 1.5 h. The solution was then
poured into 1 N hydrochloric acid, extracted with dichlorome-
thane, dried over anhydrous magnesium sulfate, and solvent re-
moved under reduced pressure. The crude oil was puri¢ed by
preparative thin layer chromatography (7.5% methanol^chloro-
form), where upon elution with ethyl acetate o¡ the silica resulted
in formation of a white precipitate. Solvent was removed under
reduced pressure, and the residue redissolved in methanol. Sepa-
ration of the precipitate and solvent by centrifugation, allowed
separation of the pure triphenylethylene Z isomer as a white solid
(2.3 mg, 0.0062 mmol, 9% yield), and a 2:1 mixture of the E :Z
isomers of 6 as a yellow oil (5.2 mg, 0.014 mmol, 20% yield): Rf
0.31 (5% methanol^chloroform); 1H NMR (CD3OD) of E :Z
mixture N 0.85 (t, J = 7.6 Hz, 4.5 H), 2.44 (q, J = 7.6 Hz, 3 H),
6.23 (d, J = 16.0 Hz, 1 H, E isomer), 6.34 (d, J = 8.8 Hz, 1 H),
6.41 (d, J = 16.0 Hz, 0.5 H), 6.58 (d, J = 8.4 Hz, 1 H), 6.71 (d,
J = 8.8 Hz, 2 H), 6.82 (d, J = 8.0 Hz, 2 H), 6.96 (d, J = 8.4 Hz,
2 H), 7.00^7.10 (m, 7.5 H), 7.14 (d, J = 8.4 Hz, 2 H), 7.19 (d, J = 8.4
Hz, 1 H), 7.43 (d, J = 16.0 Hz, 1 H, E isomer), 7.51 (d, J = 8.0 Hz,
1 H), 7.62 (d, J = 16.0 Hz, 0.5 H, Z isomer); 13C NMR (CD3OD)
of E isomer 13.80, 30.01, 116.04, 118.56, 127.42, 128.23, 129.02,
130.85, 131.67, 132.49, 133.12, 135.53, 139.64, 143.57, 144.09,
146.06, 147.41, 157.58, 170.52 ppm; 1H NMR (CD3OD) of Z
isomer N 0.86 (t, J = 7.6 Hz, 3 H), 2.40 (q, J = 7.6 Hz, 2 H),
6.35 (d, J = 8.8 Hz, 2 H), 6.41 (d, J = 16.0 Hz, 1 H), 6.59 (d,
J = 8.8 Hz, 2 H), 7.03^7.12 (m, 5 H), 7.20 (d, J = 8.0 Hz, 2 H),
7.52 (d, J = 8.4 Hz, 2 H), 7.61 (d, J = 16.0 Hz, 1 H); HRMS (EI)
exact mass calculated for C25H22O3 : 370.1569, found: 370.1562.
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